Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Mayo Clinic’s cardiac (CV) remote monitoring service uses the compact MoMe Kardia cardiac monitoring device that yields a continuous, 24/7 stream of a patient’s ECG and motion data, no matter their location. Any troubling or burgeoning...
A decade-long search for answers ends at Mayo Clinic: Tyler Hart - Insights
After years of misdiagnosis, Tyler Hart found answers at Mayo Clinic, discovering he had NF155-IgG4 autoimmune nodopathy instead of CIDP
Multiomics: A new model for identifying biomarkers to predict severe COVID-19 outcomes - Insights
In a groundbreaking study, Mayo Clinic investigators have developed a multiomic molecular method to predict clinical COVID-19 (SARS-CoV-2) outcomes better than traditional cytokines. Using a machine-learning-based prediction model, the team...
BioPharma Diagnostics - Insights
BioPharma Diagnostics bring Mayo Clinic quality and expertise to collaborative engagements with biopharma, diagnostic and biotech companies to support a range of services, including clinical trial development, assay development, research...
Mayo Clinic has been recognized as the No. 1 gastroenterology and gastrointestinal surgery hospital in the nation by U.S. News & World Report every year since 1990. Backed by the experience and knowledge of more than 140 digestive disease...
STAT testing is available on a limited basis for patients with a suspected or known inborn error of metabolism when there is an increased risk of illness or death due to metabolic decompensation or when testing will allow for emergent...
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Offering more than 150 oncology-specific tests in nine subspecialty areas, Mayo Clinic Laboratories’ cancer tests are developed by an experienced team of board-certified geneticists, genetic counselors, and physicians.
New tests launched in March - Insights
In March 2023, Mayo Clinic Laboratories announced twenty nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.